A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 715-718

  Suda, Katie J ^a   Hicks, Lauri A ^b   Roberts, Rebecca M ^b   Hunkler, Robert J ^c   Danziger, Larry H ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c IQVIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antibiotic; Expenditures; Healthcare setting; Outpatient

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HOSPITAL PATIENT; LONG TERM CARE; OUTPATIENT; UNITED STATES;

ANTI-BACTERIAL AGENTS; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 84873600748     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks445     Document Type: Article

References (16)

1. Centers for Medicare and Medicaid Services. National Health Expenditures. http://media.mcknights.com/documents/20/national_health_ expenditures_4937.pdf (28 July 2012, date last accessed).
2. IMS Health. Biopharma Market Forecasts and Trends. http://www.imshealth.com/portal/site/ims/menuiten.d248e29c86589c9c30e81c033208c22a/?vganextoid=4b8c410b6c718210VgnVCM100000ed152ca2RCRD&vgnextchannel=5687ce9e0a99f210VgnVCM10000071812ca2RCRD&vgnextfmt=default (25 October 2012, date last accessed).
3. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2007. Am J Health-Syst Pharm 2007; 64: 298-314.
4. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2008. Am J Health-Syst Pharm 2008; 65: 234-53.
5. Hoffman JM, Doloresco F, Vermeulen LC et al. Projecting future drug expenditures - 2010. Am J Health-Syst Pharm 2010; 67: 919-28.
6. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64.
7. Boardman C, IMS Health Incorporated. System and Method for Estimating Product Distribution Using a Product Specific Universe, US Patent No. 7,174,304, 2007.
8. Garbutt JM, Banister C, Spitznagel E et al. Amoxicillin for acute rhinosinusitis: a randomized controlled trial. JAMA 2012; 307: 685-92.
9. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009; 302: 758-66.
10. McCaig LF, Hicks LA, Roberts RM et al. Office-related antibiotic prescribing for persons aged,14 years-United States, 1993-1994 to 2007-2008. MMWR 2011; 60: 1153-6.
11. Polgreen PM, Yang M, Laxminarayan R et al. Respiratory fluoroquinolone use and influenza. Infect Control Hosp Epidemiol 2011; 32: 706-9.
12. Werner NL, Hecker MT, Sethi AK et al. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 2011; 11: 187.
13. Wong-Beringer A, Nguyen LH, Lee M et al. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy 2009; 29: 736-43.
14. Davey P, Parker S. Cost effectiveness of once-daily oral antimicrobial therapy. J Clin Pharmacol 1992; 32: 706-10.
15. The Kaiser Family Foundation. Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain. 2005. http://www.kff.org/rxdrugs/ upload/follow-the-pill-understanding-the-u-s-commercial-pharmaceuticalsupply-chain-report.pdf (28 July 2012, date last accessed).
16. Steinman MA, Gonzales R, Linder JA et al. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138: 525-33.